As a “next generation” small molecule checkpoint inhibitor, RRx-001 stimulates both the innate and adaptive immune systems and is a combination partner for chemotherapy, immunotherapy and targeted agents.
Multiple different viruses with an almost unlimited number or transgene options have been developed to treat patients with multiple tumor types and mutations.
SMALL MOLECULE INHIBITORS
To accelerate the pace of clinical development and hopefully shorten the time to FDA approval, several small molecule inhibitors with Phase 1 and Phase 2 clinical data that were abandoned or “shelved” for any number of non-safety–related reasons have been repositioned or “repurposed” as anticancer agents via a proprietary EpicentRx dosing strategy.
The application of viruses engineered to express tumor antigens and immunostimulatory cytokines induce an immune response, which potentially leads to durable tumor rejection.
Cell-based therapies are versatile therapeutic platforms that act as replication factories for EpicentRx oncolytic viruses, shield the therapeutic payload from the immune system and are designed to deliver the viruses directly to the site of the metastases.
A Phase 3 Clinical Stage Pharmaceutical Company
With a prolific platform of small molecule therapies, cell based therapies, vaccines and oncolytic viruses, the central focus of EpicentRx Inc., a privately owned physician-led phase 3 clinical-stage pharmaceutical company located in San Diego, California, is on anticancer immunization and chemo/radioprotection of normal tissues. As a company of actively practicing oncologists/internists we at EpicentRx take cancer very very personally (in a literal and figurative sense) with the plight of the patient serving first and foremost as the motivation to customize or personalize our platform of immunotherapies both to individuals that are otherwise out of options and to groups of individuals with common and in many cases currently undruggable mutations.
For further information, please contact us.